U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07284069) titled 'Senicapoc and Perampanel for Newly Diagnosed Glioblastoma' on Nov. 14.
Brief Summary: Glioblastoma is the most common and aggressive form of brain cancer in adults. Despite surgery, radiotherapy, and chemotherapy, most patients only live about one year after diagnosis. There is an urgent need for new and better treatments.
Recent research has shown that glioblastoma cancer cells communicate with surrounding brain cells through electrical signals that help the tumor grow and resist treatment. Two existing drugs, perampanel (used for epilepsy) and senicapoc (previously tested for blood disorders), may block these harmful signals. Lab...